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Splice modulating antisense 
oligonucleotides restore some acid-
alpha-glucosidase activity in cells 
derived from patients with late-
onset pompe disease
May thandar Aung-Htut1,5,6, Kristin A. Ham1,5,6, Michel tchan2,3, Russell Johnsen1, 
Frederick J. Schnell4, Sue fletcher1,5,6* & Steve D. Wilton1,5,6*
pompe disease is caused by mutations in the GAA gene, resulting in deficient lysosomal acid-α-
glucosidase activity in patients, and a progressive decline in mobility and respiratory function. Enzyme 
replacement therapy is one therapeutic option, but since not all patients respond to this treatment, 
alternative interventions should be considered. One GAA mutation, c.-32-13T > G, impacts upon 
normal exon 2 splicing and is found in two-thirds of late-onset cases. We and others have explored a 
therapeutic strategy using splice modulating phosphorodiamidate morpholino oligomers to enhance 
GAA exon 2 inclusion in the mature mRNA of patients with one c.-32-13T > G allele. We designed 20 
oligomers and treated fibroblasts derived from five patients to identify an oligomer sequence that 
maximally increased enzyme activity in all fibroblasts. The most effective splice correcting oligomer 
was chosen to treat forced-myogenic cells, derived from fibroblasts from nine patients carrying the 
c.-32-13T > G mutation. After transfection, we show increased levels of the full-length GAA transcript, 
acid-α-glucosidase protein, and enzyme activity in all patients’ myogenic cells, regardless of the nature 
of the mutation in the other allele. This data encourages the initiation of clinical trials to assess the 
therapeutic efficacy of this oligomer for those patients carrying the c.-32-13T > G mutation.
Intronic variations that lead to aberrant splicing events, such as exon loss or the retention of intronic sequence 
in the mature mRNA in the form of pseudo-exons, have been reported in many genes1,2. Most recently, Milasen, 
a splice switching compound targeted to the CLN7 pseudo-exon mutation in one Batten disease patient, was 
granted approval by the US Food and Drug Administration3. There is growing interest in the use of splice switch-
ing antisense oligonucleotides (AOs) as therapeutic agents to treat serious inherited diseases. At present, three 
splice switching AOs, Vyondys 534, Exondys 515, and Spinraza6, have been approved by the US Food and Drug 
Administration as treatments for a subset of patients with Duchenne muscular dystrophy and spinal muscular 
atrophy, respectively.
The late-onset form of Pompe disease, also known as glycogen storage disease type II (GSD II), presents as a 
suitable candidate for AO therapy, since approximately two-thirds of the adult Pompe patients harbour a common 
disease-causing mutation: c.-32-13T > G7. The incidence of this variant is higher in Caucasians and identified in 
ninety percent of the adult-onset Pompe patients8. This mutation is known to cause complete skipping of exon 
2 from most GAA transcripts (Supplementary Fig. S1)9,10, and disease onset and severity is modestly correlated 
with the residual lysosomal acid-α-glucosidase (GAA) activity in those patients11–13. Generally, less than 1% of 
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normal GAA activity is observed in those presenting with the infantile form of the disease. Juvenile-onset patients 
generally have less than 10% GAA activity, while less than 30% activity is observed in adult-onset patients.
Since Pompe disease arises from an insufficiency of the GAA enzyme, enzyme replacement therapy (ERT) is 
one therapeutic option. Intravenous administration of recombinant human GAA, Lumizyme (alglucosidase alfa, 
also marketed as Myozyme), manufactured by Sanofi-Genzyme, Framingham, MA14, shows modest responses 
with limited efficacy in mitigating muscle weakness and respiratory dysfunction15,16 and 25% of patients may not 
respond to the treatment17. Consequently, the second generation of recombinant GAA, avalglucosidase alfa, with 
increased mannose 6-phosphate residues to enhance GAA uptake was developed18. A phase 1 study on safety, 
pharmacokinetic and pharmacodynamic of avalglucosidase alfa in late-onset Pompe patients showed that the 
enzyme was well-tolerated, however anti-avalglucosidase alfa antibodies were detected in 90% of the patients who 
have not previously received ERT19. In addition, the first human, open-label, phase 1/2 trial for combination ther-
apy of a modified GAA, in conjunction with a small molecule pharmacological chaperone, has also been initiated 
(NCT02675465, https://clinicaltrials.gov).
Gene replacement therapy by intra-diaphragmatic injections of an adeno-associated viral vector encoding 
the human GAA cDNA has been evaluated20. However, immune responses against the viral capsid protein and 
transgene were detected in these patients. While the development of antibodies against the viral capsid is a major 
drawback of gene therapy, co-administration of an an immunosuppressive regimen and the vector carrying 
the GAA transgene is currently being investigated (NCT02240407, https://clinicaltrials.gov), as are many other 
strategies to improve gene therapy for Pompe disease (for detail review see21). Consequently, there is a strong 
justification for the investigation and evaluation of alternative therapies.
We have extensive experience in designing splice switching AOs, including those to treat Duchenne muscular 
dystrophy (DMD)22 and spinal muscular atrophy23,24. We designed and tested numerous AOs to prevent aberrant 
GAA exon 2 splicing and enhance normal processing of the GAA transcript in late-onset Pompe patient-derived 
fibroblast cell strains carrying the common c.-32-13T > G mutation (subsequently published in the patent appli-
cation WO2015035231 A1, 5 September 2014). van der Wal et al. also reported AO sequences that prevent aber-
rant exon 2 splicing in patients with the c.-32-13T > G mutation using a vectorised U7 snRNA AO expression 
system25,26. Using a minigene approach and fibroblasts derived from a patient possessing the c.-32-13T > G muta-
tion, Goina et al. were able to correct exon 2 splicing and rescue GAA enzyme production using a combination of 
three morpholinos targeting splicing silencers within GAA exon 227. Here, we report AO sequences that showed 
consistent improvement in GAA activity in MyoD-induced myogenic cells derived from nine patients.
The well-established PMO safety profile shown in DMD patients who have received weekly infusions of a 
PMO over nine years28,29 supports further development of a PMO splice switching intervention for late-onset 
Pompe disease. Since these patients have already been exposed to full-length GAA and no exogenous proteins are 
being administered, immunogenic responses are not anticipated.
Results
Characterisation of patients -derived fibroblasts. The Pompe patient fibroblasts GM00443 and 
GM11661, purchased from Coriell Cell Repositories are designated as C 1 and C 2, respectively and those from 
Westmead Hospital, Sydney, Australia as WM 1 to 9. The patient cell strains, WM 3 and 6, were not included in 
this study as these cells either did not survive or had a considerably reduced proliferation rate (Table 1).
We confirmed the c.-32-13T > G mutation on one allele in all patients, and the previously known second 
mutations for patient C 2, WM 1, 4, and 7 (Table 1 and Supplementary Fig. S1). We identified the second muta-
tions for patients, C 1, WM 2, 5, 8, and 9 (Table 1 and Supplementary Fig. S1), as they were not previously 
characterised. Nonsense mutations, likely to induce nonsense-mediated decay (NMD) of the GAA transcripts, 
were found in patients C 1, WM 1, WM 4, WM 5 and WM 8. Lower levels of the full-length GAA transcript were 
consistently evident in these patients after amplification across exons 1 to 5 using RT-PCR and qPCR analysis 
(Fig. 1a). Highly efficient NMD of the GAA transcripts was apparent since these nonsense mutations were not 
found by DNA sequencing of the RT-PCR amplicons derived from the patients. Cryptically spliced SV2 (missing 
entire exon 2) and SV3 (partial exon 2) transcripts were present in all patients-derived fibroblasts. Due to the 
GC-rich nature of the template, additional unidentified bands, reported by others27 were also present. We found 
that the c.1128_1129delinsC mutation promotes inclusion of part of intron 6 in 20-30% of the mature GAA 
Patient ID Source Our ID
Mutations
RemarkAllele 1 Allele 2
GM00443 Coriell C 1 c.-32-13T > G c.2608C > T (p.Arg870X) c.2608C > T causes NMD
GM11661 Coriell C 2 c.-32-13T > G Genomic deletion of exon 18
Patient 1 Westmead WM 1 c.-32-13T > G c.2074C > T (p.Gln692X) c.2074C > T causes NMD
Patient 2 Westmead WM 2 c.-32-13T > G c.1910_1918del (p.Leu637_Val639del)
Patient 4 Westmead WM 4 c.-32-13T > G c.1128_1129delinsC (p.Tyr376CysfsX16) c.1128_1129delinsC cause intron 6 inclusion, NMD
Patient 5 Westmead WM 5 c.-32-13T > G c.1548G > A (p.Trp516X)  c.1548G > A causes NMD
Patient 7 Westmead WM 7 c.-32-13T > G c.953T > C (p.Met318Thr)
Patient 8 Westmead WM 8 c.-32-13T > G c.1128_1129delinsC (p.Tyr376CysfsX16)  c.1128_1129delinsC cause intron 6 inclusion, NMD
Patient 9 Westmead WM 9 c.-32-13T > G c.1082C > G (p.Pro361Arg)
Table 1. Patient cell strain summary.
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transcripts (Supplementary Fig. S1) from cell lines WM 4 and 8, leading to a stop codon after p.Gly359. We also 
confirmed an in-frame deletion of exon 18 from the GAA transcript in patient C 2 (Supplementary Fig. S1).
Correctly spliced normal GAA transcript with full exon 2 inclusion was quantitated using qPCR for all 
untreated fibroblasts from patients and two healthy individuals, H 1 and H 2 (Fig. 1a). The total functional 
full-length GAA transcript expression varies between the two healthy fibroblasts. All the patient-derived fibro-
blasts (C 1, WM 1, 4, 5 and 8) carrying nonsense mutations showed lower levels of the full-length GAA transcript 
than those carrying the in-frame deletions or missense mutation (C 2, WM 2, 7 and 9).
The residual GAA activity in patient-derived fibroblasts was analysed and compared to that measured in 
fibroblasts from H1 and H2 (Fig. 1b). GAA activity in the H 2 cells was approximately half that in H 1 cells, which 
is consistent with the lower GAA transcript expression determined by qPCR. In this study, the GAA activity in 
patient-derived fibroblasts was less than 40% of that assayed in H 2 cells. Analysis of GAA protein by western 
blotting supports the observation that all patient-derived fibroblasts have lower GAA protein levels than the two 
healthy individuals (Fig. 1b).
Antisense oligonucleotide design and treatment in fibroblasts. In order to identify splice motifs 
involved in exon 2 selection during pre-mRNA processing of the c.-32-13T > G GAA transcript, we analysed GAA 
intron 1, exon 2 and intron 2 using SpliceAid 230. Several AOs targeting the predicted binding motifs for hnRNP 
H and I, and MBNL1, known to mediate exon exclusion, were designed (Table 2, Fig. 2a and Supplementary 
Fig. S2). The PMO sequences 1-3, 4-7, 8-12 and 18-20 partially overlap. The PMOs were delivered into patient 
fibroblasts (C 1, C2, WM 1, WM 2, and WM 4) using nucleofection. GAA enzyme activity assays were performed 
in triplicate, four days after PMO treatment, to identify oligomers that promote GAA exon 2 retention in the 
mature transcript (Fig. 2b and Supplementary Fig. S2).
Treatment with PMO 15 consistently increased GAA activity in three different patient-derived fibroblast 
strains, while PMO 5 and 13 also increased GAA activity in two or more patient cell strains. Since many PMOs 
failed to increase GAA activity, any improvement in GAA activity must be attributed to the PMO treatment. 
Figure 1. GAA transcript and GAA protein expression and activity of nine Pompe patients compared to two 
healthy control fibroblasts. (a) RT-PCR products of GAA transcript amplified from exon 1 to 5, and qPCR 
analysis of GAA transcript with full-length exon 2 using RNA isolated from fibroblasts derived from patients 
(C 1, C 2, WM 1, WM 2, WM 4, WM 5, WM 7, WM 8 and WM 9) and two healthy individuals (H 1 and H 2). 
The qPCR analysis was performed as the relative expression of GAA transcript compared to TBP transcript, 
encoding TATA-box binding protein, and is presented as the mean fold change ±SDs of triplicates compared 
to H 1 (healthy 1). SV2/3; splice variant 2/3. −; no template control. (b) GAA activity (mean ± SDs of at least 
three biological replicates) and protein found in nine patients and two healthy individuals derived fibroblasts. β 
tub; beta-tubulin, β act; beta-actin. The densitometric analysis of the western blot is shown as a bar graph below 
the Western image. The gels were cropped for presentation, and full-size gels are presented in Supplementary 
Fig. S5.
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PMOs 13 and 15 were further titrated to demonstrate concentration-dependent effects in patient C 1 and PMO 
15 in C 2 fibroblasts (Fig. 2c). A control PMO sequence (GTC) from Gene Tools was included in all experi-
ments as a sham transfection experimental control. An apparent dose-dependent increase in GAA activity was 
observed in both patient-derived fibroblasts, with a better response to PMO 15 seen in C 1 fibroblasts compared 
to C 2. Additional analyses were performed to confirm that the elevated GAA activity correlated with changes 
in full-length GAA transcript and GAA protein expression, and it was the case for both patient cell strains. Both 
beta-tubulin and beta-actin were analysed and used as reference loading controls on western blots. Nucleofection 
with the GTC PMO caused a slight knockdown in GAA protein expression in both cell strains, possibly due to 
the nucleofection process, although overall GAA activity was not significantly altered compared to the untreated 
samples. Neither PMO 13 nor 15 had a significant effect on GAA activity and GAA transcript when nucleofected 
into fibroblasts derived from H 1, however a slight decrease in GAA protein level was observed after PMO 15 
treatment (Supplementary Fig. S2).
Antisense oligonucleotide treatment in myogenic cells. A characteristic feature of Pompe disease 
is the accumulation of glycogen in skeletal muscle. Therefore, the PMOs that induced enhanced GAA activity in 
patient-derived fibroblasts were also evaluated in fibroblasts forced into the myogenic lineage by transduction 
with a MyoD expressing adenovirus (Fig. 3)31.
Variable levels of the muscle-specific protein desmin were detected in most patient-derived myogenic cells, 
indicating transformation of fibroblasts into the myogenic lineage (Fig. 3a), except for the WM 7 cell strain. The 
levels of desmin protein were low in MyoD induced C 1 and WM 9 cells compared to the other MyoD induced 
cell strains. Total GAA protein found in all patient-derived myogenic cells was generally less than 50% of that 
present in H 2. We also confirmed the presence of GAA transcript isoforms SV2 and 3 in all patient myogenic 
cells (Fig. 3a), affirming myogenic conversion did not alter the GAA spliceoforms identified in the fibroblasts.
We then treated myogenic cells derived from patients C1, C 2, WM 1, WM 2 and WM 4 with PMO 2, 3, 5, 6, 
13 and 15, selected according to the outcome of the AO screen in fibroblasts. Activity of GAA was analysed six 
days after PMO delivery into these myogenic cells (Fig. 3b and Supplementary Fig. S3). PMO 15 increased GAA 
activity in all the patient cells tested. The greatest improvement was observed in patient cell strains WM 1 and C 
1, with approximately 2.5 fold increase in GAA activity. (Supplementary Fig. S3).
To further confirm PMO 15 as the lead candidate in correcting GAA transcript expression and increasing 
functional protein levels, patient-derived myogenic cells were treated with different concentrations of PMO 
15 and GAA transcript, GAA activity and protein levels were analysed (Fig. 3c and Supplementary Fig. S4). 
A dose-dependent increase in GAA activity was observed in all patients’ myogenic cells, and an increase 
in full-length GAA transcript retaining exon 2 was also verified. For western analysis, both beta-tubulin and 
beta-actin were used as loading controls. However, in some patients’ myogenic cells (patient WM 2, WM 7 and 
WM 9) the relative expression levels of beta-tubulin to beta-actin were altered by some treatments. A higher 
molecular weight GAA protein corresponding to the 95 kD intermediate protein isoform was increased in the 
myogenic cells. Overall, there was a consistent increase in GAA protein expression after treatment with PMO 15.
We repeated PMO 13 and 15 treatments at least three times in all patient cell strains, except WM 8, inde-
pendently seeded and transformed into myogenic cells, and consistently observed an increase in GAA activity 
Name Coordinates Sequences (5′-3′)
PMO 1 c.-33 (+6 + 27) GCG GGG CAG AGC TCA GGT GT
PMO 2 c.-33 (+10 + 29) CAG CGC GGG GCA GAC GTC AG
PMO 3 c.-33 (+14 + 33) CCG GCA GCG CGG GGC AGA CG
PMO 4 c.-33 (+17 + 36) CCG CCG GCA GCG CGG GGC AG
PMO 5 c.-33 (+24 + 43) GAT GTT ACC GCC GGC AGC GC
PMO 6 c.-33 (+28 + 47) CTG GGA TGT TAC CGC CGG CA
PMO 7 c.-33 (+32 + 51) GCT TCT GGG ATG TTA CCG CC
PMO 8 c.-32 (−509-490) TCT CGA ACT CCT GAG CTC AA
PMO 9 c.-32 (−500-481) CCA GGC TGG TCT CGA ACT CC
PMO 10 c.-32 (−487-468) TTT GCC ATG TTA CCC AGG CT
PMO 11 c.-32 (−480-461) ACG GGA TTT TGC CAT GTT AC
PMO 12 c.-32 (−475-456) TAG AGA CGG GAT TTT GCC AT
PMO 13 c.-32 (−179-160) GAG AGG GCC AGA AGG AAG GG
PMO 14 c.-32 (−99-75) GAC ATC AAC CGC GGC TGG CAC TGC A
PMO 15 c.-32 (−74-55) GGC TCT CAA AGC AGC TCT GA
PMO 16 c.170_194 GGC CCT GGT CTG CTG GCT CCC TGC T
PMO 17 c.546 (+14 + 30) TGG CCG CCG CCC CCG CCC
PMO 18 c.546 (+40 + 59) TGT CGA TGT CCA CGC GCA CC
PMO 19 c.546 (+53 + 72) GTG AGG TGC GTG GGT GTC GA
PMO 20 c.546 (+67 + 86) GCA CCC CAC CCT TGT GAG GT
Table 2. Coordinates and sequences of AOs used in this study.
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Figure 2. Preliminary screening for the best PMO sequences that increased GAA activity in patientsderived 
fibroblasts. (a) The relative annealing positions of the AOs synthesised as PMOs are shown. PMOs are indicated 
as solid lines with the corresponding number shown above. Exons are shown as boxes and introns as lines (not 
drawn to scale). (b) The improvement of GAA activity in treated compared to untreated patient C 1 and C 2 
derived fibroblasts. Data represent the mean fold change ±SDs of two biological replicates (n = 2). (c) qPCR, 
GAA enzyme activity (average fold change ±SDs of two biological replicates) and western analysis of patient 
C 1 and C 2 fibroblasts treated with different dosages of PMO 13, 15 and GTC (Gene Tools Control). UT; 
untreated. β tub; beta-tubulin, β act; beta-actin. The densitometric analysis of the western blot is shown as a 
bar graph below the Western image. The gels were cropped for presentation, and full-size gels are presented in 
Supplementary Fig. S5. GAA assays were performed in triplicate.
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(Fig. 3d). We did not perform biological replicates for WM 8 as this patient had an identical second mutation to 
WM 4, and the increase in GAA activity in a single experiment mirrored the activity observed in WM 4. In addi-
tion, we also performed myogenic conversion of both H 1 fibroblasts and nucleofected the cells with PMO 13, 15 
and GTC. Nucleofection appeared to reduce GAA activity in the healthy control cells, but there was no further 
decrease in GAA activity after PMO 13 and 15 treatments.
Figure 3. The efficiencies of selective PMOs in myogenic cells derived from the patient after forced myogenesis. 
(a) Western analysis of muscle-specific protein desmin and RT-PCR analysis of GAA transcript (exon 1 to 5)  
in patients’ and healthy controls’ fibroblasts forced into the myogenic lineage by infection with MyoD 
expressing virus. β tub; beta-tubulin, β act; beta-actin. (b) GAA activity of patient WM 1 forced myogenic cells 
after treatment with various PMOs. Data represent the mean ± SDs of triplicates. (c) qPCR analysis of GAA 
transcript with exon 2 (the mean ± SDs of triplicates), GAA activity (the mean ± SDs of triplicates) and GAA 
protein in patient WM 1 forced myogenic cells after treatment with various dosages of PMO 15, Gene Tools 
Control (GTC) and untreated (UT). (d) Comparison of GAA activity in nine patients’ and two healthy controls’ 
(H 1 and H 2) forced myogenic cell cultures after treatment with PMO 13, 15 and GTC at 50 µM and untreated 
(UT) samples. Data represent the mean ± SDs of at least three biological replicates (n ≥ 3) for patient C 1, C 2, 
WM 1, 2, 4, 5, 7, and 9. The difference of the means, compared to GTC is significant at *p < 0.05 and #p < 0.1 
using ANOVA with Bonferroni correction. No biological replicates were performed for WM 8. The gels were 
cropped for presentation, and full-size gels are presented in Supplementary Fig. S5.
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Discussion
There is a growing interest in the use of splice switching AOs as therapeutic agents, as new applications are iden-
tified and validated. The strategy outlined in this report will be relevant to the common c.-32-13T > G mutation, 
found in approximately two-thirds of adult and juvenile-onset Pompe patients. The infantile forms of GSD II arise 
from different mutations that result in minimal to undetectable levels of residual GAA activity (typically <1% of 
normal) and therefore would be unresponsive to the therapeutic strategy described here.
According to the Erasmus MC: Pompe disease GAA variant database (www.pompecenter.nl), over 500 
causative GSD II mutations have been identified, and the phenotypes vary considerably. All nine patients’ cell 
strains used in this study carry the c.-32-13T > G mutation but differ in the nature of the mutation on the second 
allele, except WM 4 and 8. We showed that all patients have less than 40% of the GAA activity found in healthy 
control sample 2 that could be attributed to low levels of the full-length GAA transcript isoform retaining exon 2, 
despite the abnormal splicing induced by c.-32-13T > G mutation32–37.
We initially used patient-derived fibroblasts for the design and evaluation of AO sequences, as this cell type is 
frequently used for diagnosis38. However, it was necessary to evaluate the expression in myogenic cells as Pompe 
disease has a myogenic presentation, and also to ensure that any tissue-specific splicing does not influence PMO 
selection. Due to the variable nature of second mutations found in all patients34–37,39,40, any improvement after 
treatment with PMO 15 must be as a result of correct GAA transcript processing to include exon 2. Furthermore, 
the annealing site of PMO 15 is located within intron 1, and contains a strong transcriptional splicing repressor10. 
We also provide evidence for an increase in GAA protein expression and most importantly, an increase in GAA 
activity that must be regarded as a significant and appropriate readout for assessing treatment effect.
While we were performing this study, van der Wal et al.25,26 reported AO mediated splice correction of exon 2 
through prevention of a pseudo-exon inclusion in the GAA transcript in two adult Pompe patients heterozygous 
for the c.-32-13T > G mutation. One patient possessed a second mutation with a frame-shifting deletion causing 
an early termination codon in exon 2, and the other patient had a missense mutation in exon 5. They undertook 
an initial AO screen using the U7 snRNA expression system, while we used nucleofection to administer the 
PMOs. In another study, Pompe patient-derived myotubes were treated in vitro with a cocktail of three PMOs 
complementary to silencer motifs in exon 2 of the GAA transcript and showed evidence of reduced glycogen 
levels27.
We report unequivocal proof-of-concept for an AO mediated therapy applicable to a large subset of late-onset 
Pompe patients. Our study importantly provides evidence of a consistent increase of GAA activity in nine 
late-onset Pompe patient-derived cells carrying the c.-32-13T > G mutation. The responses were variable between 
the nine patients cell strains, attributed to various factors including cell quality, nature of the second mutation and 
perhaps more importantly, genetic differences in splicing machinery. Although some patients-derived cell strains 
responded to numerous AOs targeting different regions in our study, we were able to ascertain a single AO that 
could consistently increase GAA activity in all nine patients tested, regardless of the second mutation.
As with many other genetic therapies, one of the major concerns is uptake of the therapeutic compound 
into the target cell or tissue. Several options that may enhance AO uptake include different routes of adminis-
tration, delivery regimens (dosage and frequency), AO backbone and chemistry, conjugation of the oligomer to 
cell-penetrating peptides41–45, aptamers46 and nanoparticles47. PMOs are known for their resistance to degrada-
tion in human serum, plasma and tissue extracts48,49. The main concern for the late-onset Pompe disease is prox-
imal myopathy rather than cardiac50 and cognitive impairment51. The encouraging clinical outcomes reported on 
Eteplirsen/Exondys 51 and Golodirsen/Vyondys 53 for the treatment of Duchenne muscular dystrophy, supports 
further studies of this AO mediated therapy for late-onset Pompe disease.
In addition, a recent gene therapy study in non-human primates showed that delivering helper-dependent 
adenovirus expressing GAA to the liver produced sufficient secreted GAA for uptake by multiple muscles52. One 
advantage of using splice switching PMOs to address Pompe patients with c.-32-13T > G mutation is that when 
delivered through intravenous injections, these compounds accumulate in the liver and kidney49. Hence, the liver 
could produce and secrete GAA enzyme that may be taken up by muscle. Though it seems counterintuitive to 
address muscle disease by targeting the liver, a few studies have shown that liver-mediated GAA secretion is a 
possible therapy for Pompe disease52–55.
One question to be considered is whether PMO 15 should be evaluated in an animal model of the GAA c.-32-
13T > G mutation before moving to clinical trials. Without doubt, the basic toxicology in two animal species 
should be undertaken, but to our knowledge, no available rodent model carries the human c.-32-13T > G muta-
tion. Furthermore, we doubt whether a transgenic humanised rodent model would process the GAA transcript in 
the same manner as human cell, such that exon 2 was predominantly lost from the mature mRNA. The human and 
mouse genomic sequence homology in that region of the GAA/ Gaa is in the order of only 50%. Accordingly, we 
propose it may be possible to tread the path set for the first DMD exon skipping study reported by Kinali and col-
leagues56: an intramuscular injection into late-onset Pompe disease patients as a single-blind, placebo-controlled, 
dose-escalation, proof-of-concept study. Although our study was performed in MyoD induced primary fibroblast 
cells, uptake of PMO into muscle cells should not be a limitation since intramuscular injection of PMO in healthy 
mouse strains have shown efficient uptake by muscle cells57. From the many lessons learned, we hope that it does 
not take more than a decade to get a splice switching treatment for GSD II into the clinic.
Methods
All cell culture reagents were purchased from Gibco, ThermoFisher Scientific, Scoresby, Australia and all chem-
icals from Sigma-Aldrich, Sydney, Australia unless otherwise stated. Sequences for all primers used in this study 
can be found in Table 3.
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Ethics approvals. The use of human cells was approved by Murdoch University Human Research Ethics 
Committee (approval 2013/156) and the Western Sydney Local Health District (WSLHD) Human Research 
Ethics Committee, Australia (approval HREC/17/WMEAD/358). Patient biopsies were collected after informed 
consent at the Westmead Hospital58. All samples were prepared and analysed in accordance with the protocols 
approved by the ethics committees of Murdoch University and WSLHD. All methods were performed in accord-
ance with the relevant guidelines and regulations58.
Cell culture. Pompe patients-derived fibroblasts GM00443 and GM11661, were purchased from Coriell 
Cell Repositories (Camden, New Jersey) and the remaining patients-derived fibroblasts were from Westmead 
Hospital, Sydney, Australia, obtained with informed consent (Approval HREC/17/WMEAD/358, SSA/17/
WMEAD/392). Experiments were performed with Murdoch University Human Research Ethics Committee 
approval 2013/156. All cells were maintained in DMEM supplemented with L-Glutamine and 10% fetal bovine 
serum (FBS) (Scientifix, Cheltenham, Australia) at 37°C in a 5% CO2 atmosphere, except GM00443 which was 
maintained in 15% FBS, MEM. Normal human primary dermal fibroblasts were used as healthy controls.
Nucleofection. All PMOs were synthesised by Sarepta Therapeutics (Cambridge, MA) with the exception 
of Gene Tools Control (GTC), which was purchased from Gene Tools, LLC (Philomath, OR). Nucleofection of 
fibroblasts was performed using the P3 Primary Cell 4D-nucleofector X kit S (32 RCT) (Lonza, Mt Waverley, 
Australia) and CA 137 program setting. Approximately 300,000 cells were nucleofected with various quantities of 
PMO (1, 0.5 and 0.05 nanomoles corresponding to 50, 25, 2.5 µM in the cuvettes) and incubated for 4 days before 
harvesting for RNA analysis and 6 days for protein analysis and GAA enzyme activity assessment. For the initial 
screening in fibroblasts, both transcript analysis and GAA activity were performed on day 4 samples.
Adenoviral transduction and nucleofection. Patients-derived fibroblasts were nucleofected with 
PMO as described above and infected with MyoD expressing adenovirus, Ad5.f50.AdApt.MyoD (Native Antigen 
Company, Oxford, UK) at a multiplicity of infection of 20031, and plated at a density of 30,000 cells per 24 well 
pre-coated with Poly D-Lysine and Matrigel. The myogenic cells were allowed to differentiate in DMEM, low 
glucose, supplemented with 5% horse serum for 4 days before harvesting for RNA transcript studies or 6 days for 
protein analysis and GAA enzyme activity assessment.
Genomic DNA extraction and PCR for sequencing. Genomic DNA was extracted using PureLink 
Genomic DNA mini kit (ThermoFisher Scientific) according to the manufacturer’s instructions. A total of 50 ng 
of DNA was amplified using TaKaRa LA Taq DNA polymerase with GC buffer II (Takara Bio USA, Inc., Clayton, 
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Table 3. Primers used in this study.
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95 °C 30 s, 55–60 °C 30 s and 72 °C 1–5 min. The cycling conditions are listed in Table 3. The PCR products were 
purified using Diffinity RapidTip and sequenced at the Australian Genome Research Facility (Perth, Australia) 
and compared to the reference GAA genomic sequence (Accession: NG_009822.1) using BLAST (https://blast.
ncbi.nlm.nih.gov/Blast.cgi)59. All variants were submitted to ClinVar (SUB6437945; SUB6703839).
RT-PCR and qPCR. Total RNA was extracted using MagMax nucleic acid isolation kits (ThermoFisher 
Scientific) according to the manufacturer’s instructions with a DNAse step included in the kit. Approximately 
125 ng of total RNA, assessed using the Nanodrop (ND-1000, ThermoFisher Scientific) for quality and quantity, 
was used to synthesise cDNA using SuperScript IV reverse transcriptase (ThermoFisher Scientific) with 200 ng 
random hexamers (ThermoFisher Scientific) in a 20 µl reaction. Transcripts were amplified using 0.5 µl of cDNA 
as the template and TaKaRa LA Taq DNA polymerase with GC buffer II (Takara Bio USA). GAA transcript was 
amplified using the primers and cycling conditions listed in Table 3. General cycling reactions included 95 °C for 
5 min, 34–35 cycles of 95 °C 30 s, 60 °C 30 s and 72 °C 2–3 min. The PCR products were fractionated on 2% agarose 
gels in Tris-Acetate-EDTA buffer. The qPCR reactions were performed using fast SYBR Green (ThermoFisher 
Scientific) and 100 nM (96.5% primer efficiency) and 500 nM (104.9% primer efficiency) primers for GAA and 
TBP transcript, respectively58. Reactions were performed in a CFX384 Touch Real-Time PCR detection system 
(Bio-Rad Laboratories Pty., Ltd., Gladesville, Australia) and GAA (Accession: NM_000152.4) transcript expres-
sion relative to the reference transcript TBP (Accession: NM_003194.4) was calculated. The cycling reactions 
included 95 °C for 1 min, 39 cycles of 95 °C 3 s, 60 °C 15 s and 72 °C 30 s. The results were analysed on the Bio-Rad 
CFX Manager Software Version 3.1 (Bio-Rad Laboratories Pty., Ltd., Gladesville, Australia; https://www.bio-rad.
com/en-au/product/previous-qpcr-software-releases?ID=OO2BB34VY). The relative expression of GAA to TBP 
mRNA was determined using the 2−ΔΔCT method60 and presented as a fold change compared to the healthy or 
Gene Tools Control treated patients-derived fibroblasts.
GAA enzyme activity assay. Cells were subjected to three freeze-thaw cycles before resuspension in 50 µl 
of lysis buffer61 (10 mM HEPES, 70 mM sucrose, 220 mM mannitol supplemented with 1 × protease inhibitors) 
and sonicated 6 times for 1 s. The cell lysate was centrifuged at 11,000 × g for 10 min at 4°C, the supernatant 
was collected and total protein concentration was measured using Pierce BCA protein assay kit (ThermoFisher 
Scientific). Approximately 3–5 µg of the total protein lysate in 10 µl volume was used for enzymatic reactions under 
two pH conditions, 3.9 (for acid-α-glucosidase activity) and 6.5 (for neutral α-glucosidase activity). GAA enzyme 
activity was initiated by adding 20 µl of 1.4 mM artificial substrate 4-Methylumbelliferyl-β-D-glucopyranoside 
(4-MUG) prepared in two 0.2 M acetate buffers, pH 3.9 and pH 6.5. The reaction was incubated at 37 °C for 1 h 
before adding 200 µl of stop buffer (0.5 M sodium carbonate, pH 10.7)58. The fluorescent signals were measured 
using FLUOstar Omega (BMG LABTECH, Mornington, Australia) with 355 nm excitation and 460 nm emission 
filters. The ratio of signals generated at pH 3.9 to those at pH 6.5 was calculated, and the results were expressed 
as a fold change, compared to the untreated or Gene Tools Control treated patients-derived fibroblasts. All assays 
were performed in triplicate.
Western blotting. Approximately 4 µg of protein, as determined by a BCA assay, was loaded onto NuPAGE 
Novex 4–12% BIS/Tris gels (ThermoFisher Scientific) and fractionated at 200 volts until the bromophenol blue 
marker was at the bottom of the gel. Gel contents were then transferred onto Pall FluoroTrans membranes (Fisher 
Biotec Wembley, Australia) and probed with rabbit anti-GAA antibody (Abcam, cat. no. 137068, Melbourne, 
Australia)26 at 1:1,000 dilution, anti-desmin antibody (ThermoFisher Scientific, cat. no. PA5-16705)62 at 1:5,000 
dilution, mouse monoclonal anti-β-tubulin antibody (DSHB, cat. no. E7, Iowa City, Iowa)63 at 1:2,000–6,000 
dilution and mouse monoclonal anti-β-actin antibody (Sigma-Aldrich, cat. no. A5316)64 at 1:100,000 dilution 
overnight at 4 °C. Polyclonal goat anti-rabbit or anti-mouse immunoglobulins/HRP (Dako, cat. no P0448 and 
D0447 respectively, North Sydney, Australia) at a dilution of 1:10,000 and Luminata Crescendo Western HRP 
substrate (Merk Millipore, Bayswater, Australia) were used for immunodetection and a serial scan of 30 s was 
performed using Fusion FX system (Vilber Lourmat, Marne-la-Vallée, France). The entire image was processed 
and densitometric analysis was performed using ImageJ (NIH; https://imagej.nih.gov/ij/download.html)65.
Statistical analysis. One-way ANOVA with Bonferroni correction was performed to determine significance 
(p < 0.05).
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information file).
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